[{"orgOrder":0,"company":"Phrontline Biopharma","sponsor":"Samsung Bioepis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Collaboration","leadProduct":"TJ108","moa":"TOP1i\/Tubulin","graph1":"Oncology","graph2":"Preclinical","graph3":"Phrontline Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phrontline Biopharma \/ Samsung Bioepis","highestDevelopmentStatusID":"4","companyTruncated":"Phrontline Biopharma \/ Samsung Bioepis"}]

Find Clinical Drug Pipeline Developments & Deals by Phrontline Biopharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : The collaboration aims to advance the development of TJ108, an antibody-drug conjugate targeting TOP1i/Tubulin, for the treatment of cancers.

                          Product Name : TJ108

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Undisclosed

                          October 20, 2025

                          Lead Product(s) : TJ108

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Samsung Bioepis

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank